Skip Nav Destination
1-25 of 25
Keywords: pulmonary hypertensionClose
Rahul Kumar, Michael H. Lee, Biruk Kassa, Dara C. Fonseca Balladares, Claudia Mickael, Linda Sanders, Adam Andruska, Maya Kumar, Edda Spiekerkoetter, Angela Bandeira, Kurt R. Stenmark, Rubin M. Tuder, Brian B Graham
Clin Sci (Lond) (2023) 137 (8): 617–631.
Published: 21 April 2023
...Rahul Kumar; Michael H. Lee; Biruk Kassa; Dara C. Fonseca Balladares; Claudia Mickael; Linda Sanders; Adam Andruska; Maya Kumar; Edda Spiekerkoetter; Angela Bandeira; Kurt R. Stenmark; Rubin M. Tuder; Brian B Graham Background: Pulmonary hypertension (PH) can occur as a complication...
Includes: Supplementary data
Anna K. Whitehead, Nicholas D. Fried, Zhen Li, Kandasamy Neelamegam, Charlotte S. Pearson, Kyle B. LaPenna, Thomas E. Sharp, David J. Lefer, Eric Lazartigues, Jason D. Gardner, Xinping Yue
Clin Sci (Lond) (2022) 136 (12): 973–987.
Published: 22 June 2022
..., the effects of nicotine alone on cardiopulmonary function remain largely unknown. Previously, we have shown that chronic nicotine vapor inhalation in mice leads to the development of pulmonary hypertension (PH) with right ventricular (RV) remodeling. The present study aims to further examine...
Includes: Supplementary data
Clin Sci (Lond) (2022) 136 (1): 163–166.
Published: 10 January 2022
...Sarah-Eve Lemay; Sebastien Bonnet; François Potus In this commentary, we discuss new observations stating that spliced X-box-binding protein 1 (Xbp1s)-DNA damage-inducible transcript 3 (Ddit3) promotes monocrotaline (MCT)-induced pulmonary hypertension (Jiang et al., Clinical Science (2021) 135 (21...
Clin Sci (Lond) (2021) 135 (21): 2467–2481.
Published: 01 November 2021
...Hongxia Jiang; Dandan Ding; Yuanzhou He; Xiaochen Li; Yongjian Xu; Xiansheng Liu Pulmonary hypertension (PH) is a life-threatening disease characterized by vascular remodeling. Exploring new therapy target is urgent. The purpose of the present study is to investigate whether and how spliced x-box...
Clin Sci (Lond) (2020) 134 (17): 2319–2336.
Published: 09 September 2020
... diseases (CVDs). Belonging to WHO classified Group I of pulmonary hypertension, PAH refers to a complex set of pulmonary vascular anomalies representing increased pulmonary vascular resistance [ 120 ]. Endothelial injury, VSMC hyperplasia and fibrosis, and development of plexiform lesions...
Xue-liang Zhou, Zhi-bo Liu, Rong-rong Zhu, Huang Huang, Qi-rong Xu, Hua Xu, Liang Zeng, Yun-yun Li, Cha-hua Huang, Qi-cai Wu, Ji-chun Liu
Clin Sci (Lond) (2019) 133 (9): 1085–1096.
Published: 09 May 2019
... pulmonary resistance methylation metabolism pulmonary hypertension Trehalose References 1. D’Alessandro A. , El Kasmi K.C. , Plecita-Hlavata L. , Jezek P. , Li M. , Zhang H. et al . ( 2018 ) Hallmarks of pulmonary hypertension: mesenchymal...
Clin Sci (Lond) (2017) 131 (16): 2063–2078.
Published: 24 July 2017
... cardiovascular physiology heart failure mitochondria pulmonary hypertension sirtuins Cardiometabolic disease (CMD) or cardiometabolic syndrome, remains one of the leading causes of morbidity and mortality worldwide. CMD is a disease entity of maladaptive cardiovascular, renal, metabolic...
Imad Al Ghouleh, Sanghamitra Sahoo, Daniel N. Meijles, Jefferson H. Amaral, Daniel S. de Jesus, John Sembrat, Mauricio Rojas, Dmitry A. Goncharov, Elena A. Goncharova, Patrick J. Pagano
Clin Sci (Lond) (2017) 131 (15): 2019–2035.
Published: 17 July 2017
... endothelial cells gremlin1 hedgehog NADPH oxidase pulmonary hypertension reactive oxygen species Despite the availability of a number of FDA-approved drugs, pulmonary arterial hypertension (PAH) remains a deadly disease with a median survival of 2.8 years from diagnosis [ 1 , 2 ]. Current...
Jie Song, Christina A. Eichstaedt, Rebecca Rodríguez Viales, Nicola Benjamin, Satenik Harutyunova, Christine Fischer, Ekkehard Grünig, Katrin Hinderhofer
Clin Sci (Lond) (2016) 130 (22): 2043–2052.
Published: 11 October 2016
... hypertension based on a customized kit and new sequencing technologies. In this manner we identified mutations in routinely assessed genes and one additional gene in PAH patients. genetics mutation analysis panel diagnostic pulmonary hypertension • In this study we present a new PAH...
Clin Sci (Lond) (2014) 127 (2): 65–76.
Published: 17 March 2014
... exchange. This pathological process may also contribute to PH (pulmonary hypertension) due to LHD. Few clinical trials have specifically evaluated lung structural remodelling and the effect of related therapies in LHD. Currently approved treatment for chronic HF (heart failure) may have direct beneficial...
Clin Sci (Lond) (2009) 116 (6): 497–505.
Published: 12 February 2009
...Tsung-Ming Lee; Chien-Chang Chen; Hsiu-Nien Shen; Nen-Chung Chang PH (pulmonary hypertension) often complicates the disease course of patients with COPD (chronic obstructive pulmonary disease) and is an indication of a worse prognosis. In the present study, we assessed whether pravastatin...
Clin Sci (Lond) (2009) 116 (6): 493–495.
Published: 12 February 2009
...Tamera J. Corte; Stephen J. Wort COPD (chronic obstructive pulmonary disease) is a significant health concern as the fourth leading cause of morbidity and mortality in the U.S.A. Although the prevalence of PH (pulmonary hypertension) in COPD is unknown, its presence is a risk factor for mortality...
Hans-Joachim Kabitz, Anja Schwoerer, Hinrich-Cordt Bremer, Florian Sonntag, Stephan Walterspacher, David Walker, Vanessa Schaefer, Nicola Ehlken, Gerd Staehler, Michael Halank, Hans Klose, Hossein A. Ghofrani, Marius M. Hoeper, Ekkehard Gruenig, Wolfram Windisch
Clin Sci (Lond) (2008) 114 (2): 165–171.
Published: 11 December 2007
... respiratory muscle function occurs in patients with PH (pulmonary hypertension); however, comprehensive investigations of respiratory muscle function, including the application of non-volitional tests, needed to verify impairment of respiratory muscle strength in patients with PH have not yet been performed...
Clin Sci (Lond) (2003) 105 (6): 647–653.
Published: 01 December 2003
...Jean-François JASMIN; Peter CERNACEK; Jocelyn DUPUIS Although activation of the endothelin (ET) system contributes to pulmonary hypertension, modifications of the cardiopulmonary ET system and its responses to chronic ET receptor blockade are not well known. To investigate this, rats were injected...
Clin Sci (Lond) (2002) 103 (4): 345.
Published: 23 August 2002
...Fuad LECHIN; Bertha VAN DER DIJS; Alex E. LECHIN bronchial asthma plasma serotonin pulmonary hypertension therapeutics. Correspondence : Dr F. Lechin (e-mail email@example.com ). 20 5 2002 The Biochemical Society and the Medical Research Society © 2002 2002...
Clin Sci (Lond) (2002) 102 (3): 253–268.
Published: 11 February 2002
... vasoactive factors. Perturbations of these systems may contribute to the pathogenesis of pulmonary hypertension. Recently, mutations in BMPR2 and ALK-1 , genes that encode members of the transforming growth factor-β (TGF-β) receptor superfamily, have been found in patients with primary pulmonary hypertension...
Toshio NISHIKIMI, Seiki NAGATA, Tatsuya SASAKI, Fumiki YOSHIHARA, Noritoshi NAGAYA, Takeshi HORIO, Hisayuki MATSUO, Hiroaki MATSUOKA, Kenji KANGAWA
Clin Sci (Lond) (2001) 100 (1): 61–66.
Published: 13 December 2000
... hypertension due to mitral stenosis. adrenomedullin mitral stenosis pulmonary circulation pulmonary hypertension The Biochemical Society and the Medical Research Society © 2001 2001 4 5 2000 13 7 2000 26 9 2000 Correspondence : Dr Toshio Nishikimi, Division of Hypertension...
Clin Sci (Lond) (1999) 97 (1): 99–102.
Published: 01 June 1999
...Ian A. FORREST; Therese SMALL; Paul A. CORRIS Inhaled epoprostenol (prostacyclin) may be used in the treatment of severe pulmonary hypertension, improving oxygenation and reducing pulmonary artery pressures. We have observed symptomatic benefits of epoprostenol in patients with congenital heart...
Mikio KAKISHITA, Toshio NISHIKIMI, Yoshiaki OKANO, Toru SATOH, Shingo KYOTANI, Noritoshi NAGAYA, Kengo FUKUSHIMA, Norifumi NAKANISHI, Shuichi TAKISHITA, Atsuro MIYATA, Kenji KANGAWA, Hisayuki MATSUO, Takeyoshi KUNIEDA
Clin Sci (Lond) (1998) 96 (1): 33–39.
Published: 01 January 1999
... patients with severe pulmonary hypertension (12 cases of primary pulmonary hypertension, 21 with chronic thromboembolic pulmonary hypertension; age 49±16 years, mean pulmonary arterial pressure 50±15 mmHg). In addition, plasma levels of adrenomedullin were measured before and after acute nitric oxide...
Clin Sci (Lond) (1994) 87 (1): 109–114.
Published: 01 July 1994
... of atrial natriuretic peptide within the pulmonary vasculature may be responsible for this effect. Modulation of atrial natriuretic peptide may have therapeutic potential in the management of conditions characterized by pulmonary hypertension and pulmonary vascular remodelling. 18 3 1993 8 2 1994...
Clin Sci (Lond) (1989) 77 (5): 515–520.
Published: 01 November 1989
... effect was undiminished. 27 4 1989 4 5 1989 © 1989 The Biochemical Society and the Medical Research Society 1989 chronic hypoxia ligustrazine pulmonary hypertension pulmonary vasodilatation Clinical Science ( 1989) 77.5 15-520 515 Effect of ligustrazine on pulmonary vascular...
Clin Sci Mol Med (1977) 53 (6): 587–593.
Published: 01 December 1977
... between the amount of emphysema and the reduction in pulmonary blood volume. Key words: bronchitis, dyedilution curves, emphysema, oxygen, pulmonary hypertension. Abbreviations: FEVl.o, forced expiratory vol- ume in 1 s; PW, pulmonary wedge pressure; RV, residual volume; TLC, total lung capacity; VC...
Clin Sci Mol Med (1977) 53 (4): 397–400.
Published: 01 October 1977
...-dihydroxyphenylalanine methyldopa pulmonary hypertension Clinical Science and Molecular Medicine (1977) 53, 397400. SHORT COMMUNICATION Effect of amethyldopa on the pulmonary vascular changes induced by chronic hypoxia in rats A. J. SUGGETT AND J. HERGET* Section of Experimental Medicine, Academic Division...
Clin Sci Mol Med (1976) 51 (s3): 575s–578s.
Published: 01 December 1976
..., and pulmonary artery pressure. Nitroprusside, although decreasing pressure and vascular resistance, caused no significant change in the other functions except for reducing pulmonary artery pressure. Minoxidil, when given orally, had the potential for causing pulmonary hypertension. This seemed explained...
Clin Sci Mol Med (1974) 46 (3): 375–391.
Published: 01 March 1974
..., but the perinuclear sarcoplasm had increased. All layers of the myocardium participated in the hypertrophy. 6 11 1973 © 1974 The Biochemical Society and the Medical Research Society 1974 hypoxia right ventricular hypertrophy pulmonary hypertension pulmonary arterioles Clinical Science...